# Pharmacology SAQ

<details><summary>Analgesics</summary><p>

- [2000A15 Opioids - Respiratory Effects](analgesics/2000A15_opioids_respiratory_effects.htm)
- [2006A07 Naloxone](analgesics/2006A07_naloxone.htm)
- [2007A03 Opioids - inter-individual variation](analgesics/2007A03_opioids_inter_individual_variation.htm)
- [2007B03 Opioids - transition from IV to oral](analgesics/2007B03_opioids_transition_from_iv_to_oral.htm)
- [2008B04 Ketamine - use in post-op analgesia](analgesics/2008B04_ketamine_use_in_post_op_analgesia.htm)
- [2009A05 Intrathecal opioids](analgesics/2009A05_intrathecal_opioids.htm)
- [2010B01 Morphine vs oxycodone](analgesics/2010B01_morphine_vs_oxycodone.htm)
- [2011A06 Remifentanil](analgesics/2011A06_remifentanil.htm)
- [2013B12 Alfentanil vs fentanyl](analgesics/2013B12_alfentanil_vs_fentanyl.htm)
- [2013C08 Opioid metabolism - morphine, pethidine and codeine](analgesics\2013C08_opioid_metabolism_morphine_pethidine_and_codeine.htm)
- [2014A10 Morphine vs tramadol](analgesics/2014A10_morphine_vs_tramadol.htm)
- [2014A11 Aspirin overdose vs paracetamol overdose](analgesics/2014A11_aspirin_overdose_vs_paracetamol_overdose.htm)
- [2015A11 Morphine PCA vs fentanyl PCA](analgesics/2015A11_morphine_pca_vs_fentanyl_pca.htm)
- [2016B12 Opioids - mechanism of analgesia](analgesics/2016B12_opioids_mechanism_of_analgesia.htm)
- [2017B12 Non-steroidal anti-inflammatory drugs](analgesics/2017B12_nsaids.htm)
- [2017B15 Tramadol](analgesics/2017B15_tramadol.htm)
- [2018A05 Opioids - therapeutic and adverse effects](analgesics/2018A05_opioids_therapeutic_and_adverse_effects.htm)
- [2019A14 Tramadol - metabolism and excretion](analgesics/2019A14_tramadol_metabolism_and_excretion.htm)

</p></details>

<details><summary>Cardiovascular Drugs</summary><p>

- [1999B12 Sodium nitroprusside](cardiovascular_drugs/1999B12_sodium_nitroprusside.htm)
- [2001A15 Esmolol vs propranolol](cardiovascular_drugs/2001A15_esmolol_vs_propranolol.htm)
- [2002B08 Vasopressin](cardiovascular_drugs/2002B08_vasopressin.htm)
- [2004B06 Glyceryl trinitrate](cardiovascular_drugs/2004B06_glyceryl_trinitrate.htm)
- [2006B01 Treatment of hypotension due to subarachnoid block](cardiovascular_drugs/2006B01_treatment_of_hypotension_due_to_subarachnoid_block.htm)
- [2006B07 Treatment of ventricular fibrillation](cardiovascular_drugs/2006B07_treatment_of_ventricular_fibrillation.htm)
- [2007A08 Treatment of chronic LV failure](cardiovascular_drugs/2007A08_treatment_of_chronic_lv_failure.htm)
- [2008A08 Treatment of myocardial ischaemia](cardiovascular_drugs/2008A08_treatment_of_myocardial_ischaemia.htm)
- [2012B05 Drugs acting on the renin-angiotensin system](cardiovascular_drugs/2012B05_drugs_acting_on_the_renin_angiotensin_system.htm)
- [2015A08 Treatment of intra-operative hypertension](cardiovascular_drugs/2015A08_treatment_of_intra_operative_hypertension.htm)
- [2016A08 Treatment of hypertension in pregnancy](cardiovascular_drugs/2016A08_treatment_of_hypertension_in_pregnancy.htm)
- [2016A09 Amiodarone](cardiovascular_drugs/2016A09_amiodarone.htm)
- [2017B07 Ephedrine vs noradrenaline](cardiovascular_drugs/2017B07_ephedrine_vs_noradrenaline.htm)
- [2018A08 Metoprolol](cardiovascular_drugs/2018A08_metoprolol.htm)
- [2018B10 Inotropes](cardiovascular_drugs/2018B10_inotropes.htm)

</p></details>

<details><summary>Haemostasis drugs</summary><p>
  
- [2004A08 Unfractionated heparin - adverse effects](haemostasis_drugs/2004A08_unfractionated_heparin_adverse_effects.htm)
- [2008B07 Anti-platelets](haemostasis_drugs/2008B07_anti_platelets.htm)
- [2011B05 Protamine](haemostasis_drugs/2011B05_protamine.htm)
- [2012B01 Warfarin](haemostasis_drugs/2012B01_warfarin.htm)
- [2014B08 Bridging from warfarin to low molecular weight heparins](haemostasis_drugs/2014B08_bridging_from_warfarin_to_low_molecular_weight_heparins.htm)
- [2017A08 Unfractionated heparin vs low molecular weight heparins](haemostasis_drugs/2017A08_unfractionated_heparin_vs_low_molecular_weight_heparins.htm)

</p></details>

<details><summary>Inhalational Anaesthetics</summary><p>

- [1999A14 Volatile anaesthetics - renal effects](inhalational_anaesthetics/1999A14_volatile_anaesthetics_renal_effects.htm)
- [2000A09 Volatile anaesthetics - cardiovascular effects](inhalational_anaesthetics/2000A09_volatile_anaesthetics_cardiovascular_effects.htm)
- [2001A12 Volatile anaesthetics - respiratory effects](inhalational_anaesthetics/2001A12_volatile_anaesthetics_respiratory_effects.htm)
- [2001B10 Nitrous oxide - adverse effects](inhalational_anaesthetics/2001B10_nitrous_oxide_adverse_effects.htm)
- [2004A01 Isoflurane - CNS effects](inhalational_anaesthetics/2004A01_isoflurane_CNS_effects.htm)
- [2005B01 Isoflurane - metabolism](inhalational_anaesthetics/2005B01_isoflurane_metabolism.htm)
- [2009A01 Minimum alveolar concentration](inhalational_anaesthetics/2009A01_minimum_alveolar_concentration.htm)
- [2010A03 Desflurane - adverse effects](inhalational_anaesthetics/2010A03_desflurane_adverse_effects.htm)
- [2011A07 Nitrous oxide - advantages and disadvantages](inhalational_anaesthetics/2011A07_nitrous_oxide_advantages_and_disadvantages.htm)
- [2012A02 Nitrous oxide - pharmacokinetics](inhalational_anaesthetics/2012A02_nitrous_oxide_pharmacokinetics.htm)
- [2013C02 Xenon - advantages and disadvantages](inhalational_anaesthetics/2013C02_xenon_advantages_and_disadvantages.htm)
- [2014B03 Malignant hyperthermia](inhalational_anaesthetics/2014B03_malignant_hyperthermia.htm)
- [2015A07 Sevoflurane - effects on muscle](inhalational_anaesthetics/2015A07_sevoflurane_effects_on_muscle.htm)
- [2017B05 Inhalational anaesthetics - rate of onset](inhalational_anaesthetics_2017B05_inhalational_anaesthetics_rate_of_onset.htm)
- [2018A03 Volatile anaesthetics - mechanism of hypnosis](inhalational_anaesthetics_2018A03_volatile_anaesthetics_mechanism_of_hypnosis.htm)
- [2018A06 Sevoflurane - rate of washout.htm](inhalational_anaesthetics/2018A06_sevoflurane_rate_of_washout.htm)
- [2019A09 Inhalational anaesthetics - wash-in curves](inhalational_anaesthetics/2019A09_inhalational_anaesthetics_wash_in_curves.htm)
- [2019A10 Sevoflurane - effects on regional circulations](inhalational_anaesthetics/2019A10_sevoflurane_regional_circulation_effects.htm)

</p></details>

<details><summary>Intravenous Anaesthetics</summary><p>
  
- [1999A16 Alpha 2 adrenoceptor agonist](intravenous_anaesthetics/1999A16_alpha_2_adrenoceptor_agonist.htm)
- [2002A11 Thiopentone and ketamine - non-CNS effects](intravenous_anaesthetics/2002A11_thiopentone_and_ketamine_non_CNS_effects.htm)
- [2002A16 Flumazenil](intravenous_anaesthetics/2002A16_flumazenil.htm)
- [2003B06 Alpha 2 adrenoceptor agonists - and limitations of clonidine](intravenous_anaesthetics/2003B06_alpha_2_adrenoceptor_agonists_and_limitations_of_clonidine.htm)
- [2004B07 Propofol - inter-invididual variatation in elimination half life](intravenous_anaesthetics/2004B07_propofol_inter_individual_variation_in_elimination_half_life.htm)
- [2006B03 Intravenous induction agents - inter-individual variation](intravenous_anaesthetics/2006B03_intravenous_induction_agents_inter_individual_variation.htm)
- [2007A04 Propofol TIVA vs ketamine TIVA](intravenous_anaesthetics/2007A04_propofol_tiva_vs_ketamine_tiva.htm)
- [2008A03 Ideal sedative](intravenous_anaesthetics/2008A03_ideal_sedative.htm)
- [2008B02 Propofol TIVA](intravenous_anaesthetics/2008B02_propofol_tiva.htm)
- [2008B03 Clonidine](intravenous_anaesthetics/2008B03_clonidine.htm)
- [2009B02 Propofol - adverse effects](intravenous_anaesthetics/2009B02_propofol_adverse_effects.htm)
- [2012A07 Ketamine TIVA](intravenous_anaesthetics/2012A07_ketamine_tiva.htm)
- [2012B02 Propofol vs sevoflurane - kinetics, CVS, CNS effects](intravenous_anaesthetics/2012B02_propofol_vs_sevoflurane_kinetics_cvs_cns_effects.htm)
- [2015A12 Intravenous induction - rate of onset](intravenous_anaesthetics/2015A12_intravenous_induction_rate_of_onset.htm)
- [2017B14 Propofol - non-CNS effects](intravenous_anaesthetics/2017B14_propofol_non_cns_effects.htm)
- [2018A07 Intravenous induction - dosing in youth, old age and shock](intravenous_anaesthetics/2018A07_intravenous_induction_dosing_in_youth_old_age_and_shock.htm)
- [2018B11 Midazolam](intravenous_anaesthetics/2018B11_midazolam.htm)
- [2019A11 Propofol TCI](intravenous_anaesthetics/2019A11_propofol_tci.htm)

</p></details>

<details><summary>Local Anaesthetics</summary><p>
  
- [2002A09 Local anaesthetic toxicity](local_anaesthetics/2002A09_local_anaesthetic_toxicity.htm)
- [2003A03 Local anaesthetics - mechanism of action](local_anaesthetics/2003A03_local_anaesthetics_mechanism_of_action.htm)
- [2004A03 Local anaesthetics - topical agents](local_anaesthetics/2004A02_local_anaesthetics_topical_agents.htm)
- [2004B02 Ropivacaine](local_anaesthetics/2004B02_ropivacaine.htm)
- [2005B03 Lignocaine - physicochemical characteristics](local_anaesthetics/2005B03_lignocaine_physicochemical_characteristics.htm)
- [2007A02 Local anaesthetics - neuraxial pharmacokinetics](local_anaesthetics/2007A02_local_anaesthetics_neuraxial_pharmacokinetics.htm)
- [2010A01 Local anaesthetics - structure-activity relationships](local_anaesthetics/2010A01_local_anaesthetics_structure_activity_relationships.htm)
- [2011A01 Local anaesthetic systemic toxicity - risk factors](local_anaesthetics/2011A01_local_anaesthetic_systemic_toxicity_risk_factors.htm)
- [2015A04 Local anaesthetics - nasal application](local_anaesthetics/2015A04_local_anaesthetics_nasal_application.htm)
- [2016A06 Local anaesthetics - rate of onset](local_anaesthetics/2016A06_local_anaesthetics_rate_of_onset.htm)
- [2017A12 Total spinal anaesthesia](local_anaesthetics_2017A12_total_spinal_anaesthesia.htm)
- [2017B08 Local anaesthetics - rate of offset](local_anaesthetics/2017B08_local_anaesthetics_rate_of_offset.htm)
- [2019A08 Local anaesthetic systemic toxicity - features](local_anaesthetics/2019A08_local_anaesthetic_systemic_toxicity_features.htm)

</p></details>

<details><summary>Miscellaneous Drugs</summary><p>
  
- [2000A12 Oxytocin](miscellaneous_drugs/2000A12_oxytocin.htm)
- [2000A14 Ester drugs](miscellaneous_drugs/2000A14_ester_drugs.htm)
- [2004B03 Anti-histamines](miscellaneous_drugs/2004B03_anti_histamines.htm)
- [2005B07 Droperidol](miscellaneous_drugs/2005B07_droperidol.htm)
- [2008A02 Diuretics](miscellaneous_drugs/2008A02_diuretics.htm)
- [2008B06 Colloids](miscellaneous_drugs/2008B06_colloids.htm)
- [2009A04 Atropine vs glycopyrrolate](miscellaneous_drugs/2009A04_atropine_vs_glycopyrrolate.htm)
- [2009A07 Serotonergic drugs](miscellaneous_drugs/2009A07_serotonergic_drugs.htm)
- [2009B03 Anti-emetics and pro-emetics](miscellaneous_drugs/2009B03_anti_emetics_and_pro_emetics.htm)
- [2010A07 Drugs acting at the nicotinic cholinergic receptor](miscellaneous_drugs/2010A07_drugs_acting_at_the_nicotinic_cholinergic_receptor.htm)
- [2010A08 Anti-depressants](miscellaneous_drugs/2010A08_anti_depressants.htm)
- [2012A03 Anti-aspiration drugs](miscellaneous_drugs/2012A03_anti_aspiration_drugs.htm)
- [2013C01 Oral hypoglycaemics](miscellaneous_drugs/2013C01_oral_hypoglycaemics.htm)
- [2014A06 Bronchodilators](miscellaneous_drugs/2014A06_bronchodilators.htm)
- [2014A13 Normal saline vs 4% albumin](miscellaneous_drugs/2014A13_normal_saline_vs_4pc_albumin.htm)
- [2014B14 Mannitol](miscellaneous_drugs/2014B14_mannitol.htm)
- [2016B11 Gentamicin](miscellaneous_drugs/2016B11_gentamicin.htm)
- [2016B15 Anti-emetics](miscellaneous_drugs/2016B15_anti_emetics.htm)
- [2018B13 Oxytocics and tocolytics](miscellaneous_drugs/2018B13_oxytocics_and_tocolytics.htm)
- [2019A13 Antibiotic chemoprophylaxis](miscellaneous_drugs/2019A13_antibiotic_chemoprophylaxis.htm)

</p></details>

<details><summary>Muscle Relaxants</summary><p>
  
- [2000B16 Atracurium vs cisatracurium](muscle_relaxants/2000B16_atracurium_vs_cisatracurium.htm)
- [2002B05 Suxamethonium - causes of prologned effect](muscle_relaxants/2002B05_suxamethonium_causes_of_prolonged_effect.htm)
- [2004A02 Non-depolarising relaxants - rate of onset](muscle_relaxants/2004A02_non_depolarising_relaxants_rate_of_onset.htm)
- [2006B04 Suxamethonium vs rocuronium - rapid sequence induction](muscle_relaxants/2006B04_suxamethonium_vs_rocuronium_rapid_sequence_induction.htm)
- [2007B06 Suxamethonium - mechanisms of phase 1 and phase 2 block](muscle_relaxants/2007B06_suxamethonium_mechanisms_of_phase_1_and_phase_2_block.htm)
- [2009B05 Non-depolarising relaxants - inter-individual variation](muscle_relaxants/2009B05_non_depolarising_relaxants_inter_individual_variation.htm)
- [2010B05 Reversal - anti-cholinesterases](muscle_relaxants/2010B05_reversal_anticholinesterases.htm)
- [2013C04 Relaxants - cardiovascular effects](muscle_relaxants/2013C04_relaxants_cardiovascular_effects.htm)
- [2014A02 Non-depolarising relaxants - log dose response curve](muscle_relaxants/2014A02_non_depolarising_relaxants_log_dose_response_curve.htm)
- [2016A04 Non-depolarising relaxants - adverse effects](muscle_relaxants/2016A04_non_depolarising_relaxants_adverse_effects.htm)
- [2016B10 Reversal - neostigmine](muscle_relaxants/2016B10_reversal_neostigmine.htm)
- [2017A06 Suxamethonium - adverse effects](muscle_relaxants/2017A06_suxamethonium_adverse_effects.htm)
- [2018A12 Reversal - neostigmine vs sugammadex](muscle_relaxants/2018A12_reversal_neostigmine_vs_sugammadex.htm)
- [2018B04 Suxamethonium vs rocuronium](muscle_relaxants/2018B04_suxamethonium_vs_rocuronium.htm)
- [2019A12 Non-depolarising relaxants - rate of offset](muscle_relaxants/2019A12_non_depolarising_relaxants_rate_of_offset.htm)

</p></details>

<details><summary>Pharmaceutics</summary><p>

- [2003A04 Intravenous drug additives](pharmaceutics/2003A03_intravenous_drug_additives.htm)
- [2013C03 Isomerism](pharmaceutics/2013C03_isomerism.htm)

</p></details>

<details><summary>Pharmacodynamics</summary><p>

- [2002B06 Tolerance and dependence - opioids](pharmacodynamics/2002B06_tolerance_and_dependence_opioids.htm)
- [2004B01 Mechanisms of drug action](pharmacodynamics/2004B01_mechanisms_of_drug_action.htm)
- [2005B02 Dose-response curves](pharmacodynamics/2005B02_dose_response_curves.htm)
- [2012B03 Tolerance and tachyphylaxis](pharmacodynamics/2012B03_tolerance_and_tachyphylaxis.htm)
- [2015A05 Synergy - sevoflurane and fentanyl](pharmacodynamics/2015A05_synergy_sevoflurane_fentanyl.htm)
- [2017A03 Synergy - propofol and remifentanil](pharmacodynamics/2017A03_synergy_propofol_remifentanil.htm)

</p></details>

<details><summary>Pharmacokinetics</summary><p>
  
- [2001B09 Clearance](pharmacokinetics/2001B09_clearance.htm)
- [2002A10 Rate of offset after a drug infusion](pharmacokinetics/2002A10_rate_of_offset_after_a_drug_infusion.htm)
- [2011B02 Compartment modelling](pharmacokinetics/2011B02_compartment_modelling.htm)
- [2012B13 Exponential functions](pharmacokinetics/2012B13_exponential_functions.htm)
- [2013C05 Volume of distribution](pharmacokinetics/2013C05_volume_of_distribution.htm)
- [2015B04 Half-life vs context-sensitive half-time](pharmacokinetics/2015B04_half_life_vs_context_sensitive_half_time.htm)
- [2017A04 CYP2D6](pharmacokinetics/2017A04_cyp2d6.htm)
- [2018B14 Transdermal kinetics](pharmacokinetics/2018B14_transdermal_kinetics.htm)
